A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 640
- Registration Number
- NCT06954961
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 161
- Registration Number
- NCT06278350
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 8
- Registration Number
- NCT06233916
- Locations
- 🇨🇳
beijing Gobroad Boren Hospital, Beijing, China
A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 45
- Registration Number
- NCT06105255
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05665699
- Locations
- 🇺🇸
Study Center, Morgantown, West Virginia, United States
🇺🇸Site Center, Bellevue, Washington, United States
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 121
- Registration Number
- NCT05504083
- Locations
- 🇨🇳
Inner Mongolia Baogang Hospital, Baotou, China
🇨🇳Beijing Chao-yang Hospital, Capital Medical University, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-08
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 22
- Registration Number
- NCT05492045
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Study to Evaluate D-1553 in Subjects With Lung Cancer
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 225
- Registration Number
- NCT05383898
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 92
- Registration Number
- NCT05379946
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Cancer Hospital of the University of Chinese Academy of Sciences,, Hangzhou, Zhejiang, China
Evaluation of PK and Safety of D-0120 and Allopurinol
- Conditions
- Healthy
- Interventions
- Drug: D-0120 in combination with Allopurinol
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT05360628
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States